Estrogen and its signaling pathway in non-small cell lung cancer(NSCLC)

Journal of Nanjing Medical University

Volumn 23, Issue 4, 2009, Pages 217-223

  Xu, Ruitong ^a   Shu, Yongqian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

EGFR; estrogen; estrogen receptor; lung cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GEFITINIB; TAMOXIFEN;

ADVANCED CANCER; BREAST CANCER; CANCER CELL; CARCINOGENESIS; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; GENOMICS; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 71649084488     PISSN: 10074376     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1007-4376(09)60059-9     Document Type: Review

References (65)

1. Muscat J.E., and Wynder E.L. Lung cancer pathology in smokers, exsmokers, and never smokers. Cancer Lett 88 (1995) 1-5
2. Travis W.D., Brambilla E., Muller-Hermelink H.K., and Harris C.C. World Health Organization classification of tumours. Pathology and Genetics of tumours of the lung, pleura, thymus and heart (2004), IARC Press, Lyon, France
3. Siegfried J.M. Women and lung cancer: does oestrogen play a role?. Lancet Oncol 2 (2001) 506-513
4. Ascenzi P., Bocedi A., and Marino M. Structure function relationship of estrogen receptor α and β: Impact on human health. Mol Aspects Med 27 (2006) 299-402
5. Bardin A., Boulle N., Lazennec G., Vignon F., and Pujol P. Loss of ER β expression as a common step in estrogen-dependent tumor progression. Endocrine Relat Cancer 11 (2004) 537-551
6. Patel J.D., Bach P.B., and Kris M.G. Lung cancer in US women: a contemporary epidemic. JAMA 291 (2004) 1763-1768
7. Taioli E., and Wynder E.L. Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (1994) 869-870
8. Stabile L.P., Davis A., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
9. Patrone C., Cassel T., Pettersson K., Pettersson K., Piao Y.S., Cheng G., et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 23 (2003) 8542-8552
10. Pietras R.J., Marquez D.C., Chen H.-W., Tsai E., Weinberg O., and Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70 (2005) 372-381
11. Ciana P., Di Luccio G., Belcredito S., Pollio G., Vegeto E., Tatangelo L., et al. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endo 15 (2001) 1104-1113
12. Pezzi V., Mathis J.M., Rainey W.E., and Carr B.R. Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol 87 2-3 (2003) 181-189
13. Niikawa H., Suzuki T., Miki Y., Suzuki S., Nagasaki S., Akahira J., et al. Intratumoral estrogens and estrogen receptors in human non small cell lung carcinoma. Clin Cancer Res 14 (2008) 4417-4426
14. Hershberger P.A., Vasquez A.C., Kanterewicz B., Land S., Siegfried J.M., and Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 4 (2005) 1598-1605
15. Hammoud Z., Tan B., Badve S., and Bigsby R.M. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15 (2008) 475-483
16. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., and Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
17. Schabath M.B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A.A., and Spitz M.R. Hormone replacement therapy and lung cancer risk: a case control analysis. Clin Cancer Res 10 (2004) 113-123
18. Ramnath N., Reid M., and Loewen G. Hormone replacement therapy and reduced risk of lung cancer in post-menopausal women. Lung Cancer 49 suppl 2 (2005) Abstr O-052.
19. Blackman J.A., Coogan P.F., Rosenberg L., Strom B.L., Zauber A.G., Palmer J.R., et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11 (2002) 561-567
20. Kreuzer M., Gerken M., Heinrich J., Kreienbrock L., and Wichmann H.E. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol 32 (2003) 263-271
21. Tansavatdi K., McClain B., and Herrington D.M. The effects of smoking on estradiol metabolism. Minerva Ginecol 56 (2005) 105-114
22. Tanko L.B., and Christiansen C. An update on the antiestrogenic effect of smoking: a literature review with the implications for researchers and practitioners. Menopause 11 (2004) 104-109
23. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50 1 (2004) 3-22
24. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol 138 (1997) 863-870
25. Omoto Y., Kobayashi Y., Nishida K., Tsuchiya E., Eguchi H., Nakagawa K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285 2 (2001) 340-347
26. Radzikowska E., Langfort R., and Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg 8 2 (2002) 69-73
27. Hershberger P.A., Vasquez C., Kanterewicz B., Land S., Siegfried J.M., and Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 4 (2005) 1598-1605
28. Coombes R.C., Hall E., Gibson L.J., Jassem J., Delozier T., Jones S.E., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
29. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11 (2005) 5084-5089
30. Ishibashi H., Suzuki T., Suzuki S., Niikawa H., Lu L., Miki Y., et al. Progesterone receptor in non-small cell lung cancerNa potent prognostic factor and possible target for endocrine therapy. Cancer Res 65 (2005) 6450-6458
31. Dabbs D.J., Landreneau R.J., Liu Y., Raab S.S., Maley R.H., Tung M.Y., et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. AnnThorac Surg 73 (2002) 403-406
32. Schwartz A.G., Prysak G.M., Murphy V., Lonardo F., Pass H., Schwartz J., et al. Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin Cancer Res 11 (2005) 7280-7287
33. Lau S.K., Chu P.G., and Weiss L.M. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 14 (2006) 83-87
34. Massaro D., Clerch L.B., and Massaro G.D. Estrogen receptor alpha regulates pulmonary alveolar loss and regeneration in female mice: morphometric and gene expression studies. Am J Physiol Lung Cell Molec Physiol 293 (2007) L222-L228
35. Mollerup S., Jorgensen K., Berge G., and Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37 2 (2002) 153-159
36. Alì G., Donati V., Loggini B., Servadio A., Dell'Omodarme M., Prati M.C., et al. Different estrogen receptor β expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathol 39 (2008) 1465-1473
37. Chung C.K., Zaino R., Stryker J.A., O′Neill Jr. M., and DeMuth Jr. W.E. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg 33 (1982) 599-604
38. Skov B.G., Fischer B.M., and Pappot H. Oestrogen receptor beta over expression in males with non small cell lung cancer is associated with better survival. Lung Cancer 59 (2008) 88-94
39. Wu C.T., Chang Y.L., Shih J.Y., and Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130 (2005) 979-986
40. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67 (2005) 335-376
41. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
42. Wu R.C., Smith C.L., and O'Malley B.W. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocrine Rev 26 (2005) 393-399
43. Likhite V.S., Stossi F., Kim K., and Katzenellenbogen B.S. Kinasespecific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Molec Endocrinol 20 (2006) 3120-3132
44. Atanaskova N., Keshamouni V.G., Krueger J.S., Schwartz J.A., Miller F., and Reddy K.B. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediateds signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21 (2002) 4000-4008
45. Miettinen P.J., Berger J.E., Meeses J., Phung Y., Pedersen R.A., Werb Z., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376 (1995) 337-341
46. Sibilia M., and Wagner E.F. Strain dependent epithelial defects in mice lacking the EGF receptor. Science 269 (1995) 234-238
47. Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U., Yee D., et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269 (1995) 230-234
48. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
49. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
50. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., and Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65 (2005) 1459-1470
51. Marquez-Garban D.C., Chen H.W., Fishbein M.C., Goodglick L., and Pietras R.J. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72 (2007) 135-143
52. Boerner J.L., Gibson M.A., Fox E.M., Posner E.D., Parsons S.J., Silva C.M., et al. Estrogen negatively regulates epidermal growth factor(EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptoroverexpressing breast cancer cells. Mol Endocrinol 19 (2005) 2660-2670
53. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17 (2003) 309-317
54. Zhang G., Liu X., Farkas A.M., Parwani A.V., Lathrop K.L., Lenzner D., et al. Estrogen receptor β functions through nongenomic mechanisms in lung cancer cells. Molec Endocrinol 23 (2009) 146-156
55. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Belani C.P., et al. Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer(NSCLC). Lung Cancer 49 suppl 2 (2005) abstr PD-071.
56. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Eickhoff J.C., Dacic S., et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung cancer (2008) 3119-3128
57. Weinberg O.K., Marquez-Garban D.C., Fishbein M.C., Goodglick L., Garban H.J., Dubinett S.M., et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 65 (2005) 11287-11291
58. Brodie A., Long B., and Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 49 (1998) S85-S91
59. Mah V., Seligson D.B., Li A., Márquez D.C., Wistuba I.I., Elshimali Y., et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 67 (2007) 10484-10490
60. Fasco M.J., Hurteau G.J., and Spivack S.D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188 (2002) 125-140
61. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
62. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
63. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
64. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
65. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346